1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Successful Treatment of Extra-Renal Noncerebral Rhabdoid Tumors with VIDE.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Extra-renal noncerebral rhabdoid tumors (ERRTs) are highly aggressive and often lethal. An optimal chemotherapy regimen for ERRT remains undetermined. We report on three pediatric patients successfully treated with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE). Two of our patients who had metastatic or refractory disease have survived more than 2 years, one disease free without myeloablative megatherapy. The treatment with high-dose alkylator therapy is reported to have a beneficial effect on survival. A VIDE regimen containing high-dose ifosfamide is feasible and appears to prolong the survival of patients with ERRT. This regimen may be a promising option for ERRT treatment without myeloablative megatherapy.

          Related collections

          Author and article information

          Journal
          Pediatr Blood Cancer
          Pediatric blood & cancer
          Wiley
          1545-5017
          1545-5009
          Feb 2016
          : 63
          : 2
          Affiliations
          [1 ] Division of Pediatric Oncology, National Cancer Center Hospital East.
          [2 ] Division of Pathology and Clinical Laboratories, National Cancer Center Hospital.
          [3 ] Division of Musculoskeletal Oncology, National Cancer Center Hospital.
          Article
          10.1002/pbc.25777
          26469354
          26a1393b-e948-4203-8366-52e589829006
          © 2015 Wiley Periodicals, Inc.
          History

          VIDE,chemotherapy,malignant rhabdoid tumor
          VIDE, chemotherapy, malignant rhabdoid tumor

          Comments

          Comment on this article